Remegen
Yantai · Founded 2008
About Remegen
RemeGen, Ltd. ("RemeGen") is a biopharmaceutical company in China dedicated to fulfilling unmet medical needs for patients with life-threatening conditions. RemeGen's main focus is research and development, manufacturing and commercialization of novel biologics, most notably monoclonal antibodies (mAb) and antibody-drug conjugates (ADCs). Headquartered in Yantai, Shandong Province, China, RemeGen has labs/offices in Beijing and California.
Company Facts
- Founded: 2008
- Operating status: Active
- Company type: For Profit
- IPO status: Public
- Employees: 1,001 – 5,000
- Estimated revenue: $100K – $500K
- Total funding: $100.0M
- Funding stage: IPO
- Last round: Private Equity (Mar 2020)
- Ticker: hkg:9995
- Website: remegen.com
- Phone: +86 05353573511
Industries & Categories
Biotechnology, Health Care, Therapeutics
Canonical: https://fsome.com/organization/remegen-22355 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.